Wolf Haldenstein Announces Investigation of Aegerion Pharmaceuticals, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating potential federal securities claims against Aegerion Pharmaceuticals, Inc. (“Aegerion” or the “Company”)(NASDAQ:AEGR) and certain of its officers and directors in connection with allegations that the Company made materially false and misleading statements regarding its compliance with certain provisions of the Food Drug and Cosmetic Act, due to the Company’s off-label marketing of its flagship hypercholesterolemia drug, Juxtapid.

According to multiple news reports published in November 2013, Aegerion’s Chief Executive Officer, Marc Beer, received a warning letter from the Food and Drug Administration regarding statements he made during broadcast interviews on CNBC’s, “Fast Money,” earlier that year, greatly overstating the effectiveness and intended uses of Juxtapid.

Then, on January 10, 2014, Aegerion received a subpoena from the Department of Justice in connection with the Company’s marketing and sale of its Juxtapid capsules. On this news, shares of Aegerion fell almost 11%, to close at $65.77 per share.

Wolf Haldenstein has represented individual and institutional investors for many years, serving as lead counsel in numerous cases in United States federal and state courts. Please visit the Wolf Haldenstein website (http://www.whafh.com) for more information about the firm.

Please contact us no later than March 17, 2014, if you own Aegerion securities and wish to discuss this matter with us, or have any questions concerning your rights and interests:

Attorney Advertising